

gel, cream, powder, foam, crystals, liposomes, spray or liquid suspension form of said compound; such that a therapeutically effective amount of said compound contacts the target platelets of said patient via systemic absorption and circulation.

15. (Original) The method according to Claim 13, wherein said systemic administration comprises infusion of said compound to target platelets via a device selected from the group consisting of a pump catheter system and a continuous or selective release device.

16-21. (Withdrawn)

### THE REMARKS

#### The amendments

In the specification and in Claim 3, the sum of  $m+n+p$  is amended from "1 to 5" to "0 to 5." Support for the amendment can be found, for example, page 4, lines 9-11, where it states  $m=0, 1, \text{ or } 2$ ;  $n=0 \text{ or } 1$ ;  $p=0, 1, \text{ or } 2$ . Therefore, the lower limit of the sum of  $m+n+p$  is 0.

In Claim 4, Formula IV is amended to delete the H on position N9 and add a bond, to correctly show a purine residue, linked through the 9-position. Formula V is amended to add a bond on N1 position to correctly show a pyrimidine residue, linked through the 1-position.

#### Restriction Election

The Examiner has required restriction to one of seven groups under 35 U.S.C. §121:

In response to the Restriction Requirement, Applicants hereby elect the invention of Group II, Claims 1, 3 and 4-15, drawn to methods of preventing or treating diseases or conditions associated with platelet aggregation using a  $P2Y_{12}$  receptor antagonist that is a dinucleotide compound of Formula I, wherein A is a nucleoside residue.

Applicants expressly reserve the right to prosecute claims directed to the remaining allegedly distinct groups in one or more continuing or divisional applications.

#### Species Election

Applicants are required under 35 USC §121 to elect a single disclosed species for

prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR §1.141.

In response to the Species Election Requirement, Applicants hereby elect the following species.

$X_1, X_2$  and  $X_3$  are all = O;

the sum of  $m+n+p$  is 1;

D1 is O;  $Y' = OR_1, Z' = OR_2$ ;

$R_1$  and  $R_2$  are residues linked directly to the 2' and 3' hydroxyls of the furanose or carbocycle via a carbon atom according to Formula III to form an acetal or ketal; where the moiety defined according to Formula III is an acetal or ketal; and

B' is a purine of general Formula IV.


Claims 1, 3 and 4-15 are readable upon the elected species.

### CONCLUSION

Applicants believe that the application is in good and proper condition for allowance. Early notification of allowance is earnestly solicited. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 463-8109.

Respectfully submitted,

Date: July 3, 2003

  
Albert P. Halluin (Reg. No. 25,227)  
Viola T. Kung (Reg. No. 41,131)

**HOWREY SIMON ARNOLD & WHITE, LLP**

301 Ravenswood Avenue

Box 34

Menlo Park, CA 94025

Ph. (650) 463-8109; (650)463-8181